Trial Profile
Pivotal phase III trial of prostate cancer vaccine [DCVax-Prostate] in patients with non-metastatic hormone-refractory prostate cancer
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 03 Feb 2013
Price :
$35
*
At a glance
- Drugs Dendritic cell vaccine-Northwest Biotherapeutics (Primary)
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- 29 Jan 2013 Northwest Biotherapeutics is planning to enter into a partnership in order to progress with this trial programme as announced in a company media release.
- 25 Apr 2012 Northwest Biotherapeutics is still intending to conduct this trial according to a company media release and the company pipeline.
- 24 Feb 2012 New trial record